Joshua J. McFarlane - Concepedia

Author

Joshua J. McFarlane

Virginia Cancer Institute

Also Known As

J. J. McFarlane, J. Mcfarlane, Joshua J. McFarlane, Joshua Jemison McFarlane, Joshua McFarlane

Publications

427

Citations

H-Index

Concepts

All Affiliations

Virginia Cancer Institute Tennessee Oncology Sarah Cannon Comprehensive Cancer Centers of Nevada Nebraska Cancer Specialists

About

Joshua J. McFarlane is an author at Virginia Cancer Institute specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	111
2	Health Sciences	1	1	16
3	Nursing	1	1	51
4	Public Health	1	1	44
5	Health Policy	1	1	44

Joshua J. McFarlane

Publications

419

Citations

H-Index

Page 1

	Year	Citations
Secondary Colorectal Carcinoma After Childhood Cancer Kerri Nottage, Joshua J. McFarlane, Matthew J. Krasin, Journal of Clinical Oncology	2012	116
Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, Clinical Genitourinary Cancer	2020	101
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer Johanna C. Bendell, Howard S. Höchster, Lowell L. Hart, The Oncologist	2017	59
Causes and Consequences of Deviation from Multidisciplinary Care in Thoracic Oncology Raymond U. Osarogiagbon, Gregory L Phelps, Joshua J. McFarlane, Journal of Thoracic Oncology NursingMedicineCancer ManagementPatient SafetyOutcomes Research	2011	51
SPIKE$: A Six-Step Protocol for Delivering Bad News About the Cost of Medical Care Joshua J. McFarlane, Jerry Riggins, Thomas J. Smith Journal of Clinical Oncology PharmacotherapyHealth Care FinanceMedical CareBad NewsSix-step Protocol	2008	44
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Joshua J. McFarlane, Mark D. Kochenderfer, Mark R. Olsen, Clinical Genitourinary Cancer	2020	32
Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study. Nicholas J. Vogelzang, Joshua J. McFarlane, Mark D. Kochenderfer, Journal of Clinical Oncology Surgical OncologyImmunodeficienciesImmunologyPharmacotherapyImmunotherapeutics	2019	16

Page 1